List of Austedo Xr drug patents

Austedo Xr is owned by Teva.

Austedo Xr contains Deutetrabenazine.

Austedo Xr has a total of 8 drug patents out of which 0 drug patents have expired.

Austedo Xr was authorised for market use on 17 February, 2023.

Austedo Xr is available in tablet, extended release;oral dosage forms.

Austedo Xr can be used as treatment of tardive dyskinesia, treatment of tardive dyskinesia; a method of treating huntington's chorea, a method of treating huntington's chorea.

The generics of Austedo Xr are possible to be released after 10 June, 2041.

AUSTEDO XR Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(7 years from now)

US9550780 TEVA Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564917 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

US10959996 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

US11446291 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

US11357772 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

US11179386 TEVA Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(14 years from now)

US11311488 TEVA Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
Jun, 2041

(18 years from now)

Do you want to check out AUSTEDO XR patents from before 2022?

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

48

United States

11

Japan

9

China

8

Australia

7

European Union

6

Hong Kong

6

Canada

5

Spain

3

Denmark

3

Brazil

3

Korea, Republic of

3

Israel

3

South Africa

2

Poland

2

Singapore

2

Argentina

EA

2

EA

2

New Zealand

2

Croatia

2

Chile

2

Portugal

2

Mexico

2

Lithuania

2

Hungary

1

India

1

RS

1

Norway

1

Cyprus

1

Peru

1

Taiwan

1

Colombia

1

Slovenia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic